MIQURE
LIVE

Serial Number

88377819

Owner

uniQure IP B.V.

Attorney

Julianne Abelman

Filing Date

Apr 9, 2019

Add to watchlist:

No watchlists yet
View on USPTO

MIQURE Trademark

Serial Number: 88377819 • Registration: 6367204

MIQURE is a trademark filed by uniQure IP B.V. on April 9, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

uniQure IP B.V.

Paasheuvelweg 25
Amsterdam 1105BP , NL

Entity Type: 99

UNIQURE BIOPHARMA B.V.

Paasheuvelweg 25
Amsterdam 1105BP , NL

Entity Type: 26

Trademark Details

Filing Date

April 9, 2019

Registration Date

June 1, 2021

Published for Opposition

March 16, 2021

Goods & Services

Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; Pharmaceutical preparations and substances for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases

Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics

Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 1, 2026 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 11, 2025 ASGN
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 4, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 4, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 4, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 4, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 4, 2025 COAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
May 26, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 26, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 26, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 26, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 26, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 26, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 26, 2023 COAR
REGISTERED-PRINCIPAL REGISTER
Jun 1, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 16, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 16, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 24, 2021 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Feb 8, 2021 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 5, 2021 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 2, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 2, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 2, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 2, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 2, 2021 CNEA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 28, 2021 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 11, 2020 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 5, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 5, 2019 GNSL
SUSPENSION LETTER WRITTEN
Dec 5, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 4, 2019 CRFA
ASSIGNED TO LIE
Dec 4, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 25, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2019 CNRT
ASSIGNED TO EXAMINER
Jun 19, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 25, 2019 NWOS
NEW APPLICATION ENTERED
Apr 12, 2019 NWAP